Bain Capital Life Sciences
No summary available yet.
BCLS is the institutional life sciences money with serious firepower and a track record that speaks volumes. Their Cerevel exit to AbbVie for $8.7B delivered a 10x return on their $250M investment, and SpringWorks IPO'd in 2019 with them owning 17%. They've cracked the code on pharma carve-outs and spin-offs better than almost anyone. They just led a $300M investment in a new company built around Bristol Myers assets, following their successful playbook with Cerevel and SpringWorks. The downside? This is big money looking for big outcomes - if you're not swinging for billion-dollar exits, you're probably not their speed. They have the Bain pedigree and consulting DNA, so expect thorough due diligence and operational involvement.
- —Best for: Late-stage biotechs with blockbuster potential and pharma spin-off opportunities
- —Watch out for: High return expectations and institutional-scale deal requirements
- —Known for: Pharma carve-out expertise and delivering massive exits like Cerevel ($8.7B)
Bain Capital Life Sciences invests in companies that focus on medical innovation and serve patients with unmet medical needs. They partner with life science companies across the globe, with a focus on driving medical innovation throughout the value chain. They specialize in buyouts, inflection capital, growth capital, turnaround investments, and private equity in pharmaceutical, biotechnology, medical device, diagnostic, and life science tool companies.
They primarily invest in Series B rounds in US-based startups, though they also do 9 Post-IPO investments averaging $71.3M and 9 Series A investments averaging $194M. Their four investment types are: Inflection Capital, Growth Capital, Fallen Angels, and Larger Private Equity Collaborations and New Company Formation. Top sectors are Life Sciences (52 investments) and High Tech (8 investments).
Bain Capital Life Sciences has a team of 29 members including 13 Partners and 9 Principals located in United States and China. The team draws upon individuals with senior experience in both the life science industry as well as public and private healthcare investing, combining deep domain expertise with the ability to tap the global reach of the broader Bain Capital platform.
Have a specific question about Bain Capital Life Sciences?
Ask Bernie →